Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

Claim 1 (previously presented): A method for the treatment, prophylaxis, or reduction of the risk of developing a menopause disorder in a female mammalian subject in need thereof, comprising:

(a) orally administering about 0.2 mg to about 50.0 mg of methyltestosterone or an enantiomer, isomer, prodrug, or salt of methyltestosterone; and

(b) administering about 0.1 mg to about 100.0 mg of estradiol or an enantiomer, isomer, prodrug, or salt of estradiol.

Claim 2 (canceled)

Claim 3 (previously presented): The method of claim 1, wherein the methyltestosterone is administered in the form of a tablet, capsule, cachet, lozenge, dispensable powder, granule, solution, suspension, emulsion or liquid.

Claims 4-7 (canceled)

Claim 8 (previously presented): The method of claim 1, wherein the estradiol or an enantiomer, isomer, prodrug, or salt of estradiol is administered percutaneously.

Claim 9 (currently amended): The method of claim ~~7~~ 8, wherein the estradiol or an enantiomer, isomer, prodrug, or salt of estradiol is administered in the form of a hydroalcoholic gel.

Claim 10 (original): The method of claim 9, wherein the hydroalcoholic gel further comprises at least one of a lower alcohol, a penetration enhancer, and a thickener.

Claim 11 (original): The method of claim 10, wherein the lower alcohol is selected from the group consisting ethanol, 2-propanol, and mixtures thereof.

Claim 12 (original): The method of claim 10, wherein the enhancer is isopropyl myristate.

Claim 13 (previously presented): The method of claim 10, wherein the thickener is polyacrylic acid.

Claim 14 (previously presented): The method of claim 1, wherein the estradiol or an enantiomer, isomer, prodrug, or salt of estradiol is administered as a percutaneous gel formulation, the formulation comprising:

(a) about 0.06% to about 10.0% estradiol or an enantiomer, isomer, prodrug, or salt of estradiol;

(b) about 0.1% to about 5.0% polyacrylic acid;

(c) about 0.1% to about 5.0% triethanolamine;

(d) about 30.0% to about 98.0% ethanol; and

(e) water in an amount sufficient to make the formulation 100%,

wherein the percentages of components are weight to weight of the formulation.

Claims15-19 (canceled)

Claim 20 (previously presented): The method of claim 1, wherein the methyltestosterone or an enantiomer, isomer, prodrug, or salt of methyltestosterone and the estradiol or an enantiomer, isomer, prodrug, or salt of estradiol are each provided as a separate component of a kit.

Claim 21 (original): The method of claim 1, wherein the mammal is a human.

Claim 22 (previously presented): The method of claim 1, wherein the methyltestosterone or an enantiomer, isomer, prodrug, or salt of methyltestosterone and the estradiol or an enantiomer, isomer, prodrug, or salt of estradiol are administered in a sequential manner.

Claim 23 (previously presented): The method of claim 1, wherein the methyltestosterone or an enantiomer, isomer, prodrug, or salt of methyltestosterone and the estradiol or an enantiomer, isomer, prodrug, or salt of estradiol are administered in a substantially simultaneous manner.

Claims 24-73 (canceled)